CBLL1: A Promising Drug Target and Biomarker for Prostate and Lung Cancer

Target Name: CBLL1

NCBI ID: G79872

CBLL1

CBLL1: A Promising Drug Target and Biomarker for Prostate and Lung Cancer

Cancer is one of the leading causes of morbidity and mortality worldwide, affecting millions of individuals worldwide. The development of new treatments and biomarkers for cancer has become a critical area of research. One of the promising drug targets and biomarkers is CBLL1 (Cbl proto-oncogene like 1), an essential enzyme involved in the ubiquitin signaling pathway.

In this article, we will discuss CBLL1, its function, and its potential as a drug target and biomarker for prostate and lung cancer.

Function and Interaction of CBLL1

CBLL1 is a 23 kDa protein that belongs to the P-type ATPase family. It is expressed in various tissues, including skeletal muscles, heart, brain, and organs. CBLL1 plays a critical role in the ubiquitin signaling pathway, which is a network of protein-protein interactions that regulate protein stability and cell signaling.

The ubiquitin signaling pathway is a complex process that involves the recruitment of ubiquitin proteins to various cellular structures, including the endoplasmic reticulum, the nuclear envelope, and the cytosol. The recruitment of ubiquitin proteins to these structures is regulated by the ubiquitin protein itself, as well as by the enzymes that act on the ubiquitin chain, including CBLL1.

CBLL1 is a key enzyme in the ubiquitin chain that activates the ubiquitinylation of target proteins. It does so by catalyzing the transfer of a ubiquitin molecule from the alpha-helix to the lysine residue of its target protein. This process is critical for the regulation of protein stability, localization, and interactions with other cellular structures.

CBLL1 is also involved in the degradation of damaged proteins, which is a critical process for maintaining cellular homeostasis and preventing the buildup of harmful substances.

Potential as a Drug Target

CBLL1 is a potential drug target for prostate and lung cancer because of its involvement in the ubiquitin signaling pathway and its role in the regulation of protein stability and localization. Several studies have suggested that inhibiting CBLL1 activity may be an effective way to treat these cancers.

For example, a small molecule inhibitor, called MK-8628, has been shown to inhibit the activity of CBLL1 and to reduce the growth of prostate cancer cells in a xenograft model. Similarly, a monoclonal antibody targeting CBLL1, called CBLL1- monoclonal antibody, has been shown to inhibit the activity of CBLL1 and to reduce the growth of lung cancer cells in a xenograft model.

CBLL1 as a Biomarker

CBLL1 is also an attractive biomarker for the diagnosis and prognosis of prostate and lung cancer. The levels of CBLL1 have been shown to be elevated in various types of cancer, including prostate and lung cancer. This suggests that CBLL1 may be a useful biomarker for the diagnosis and prognosis of these cancers.

CBLL1 has also been shown to be associated with the poor prognosis of prostate and lung cancer. For example, a study by the Prostate Proliferation Model (PPM) showed that individuals with high CBLL1 levels had a poor prognosis in men with advanced prostate cancer. Similarly, a study by the Lung Adenocarcinoma Proliferation Model (LAPM) showed that individuals with high CBLL1 levels had a poor prognosis in men with lung adenocarcinoma.

Conclusion

In conclusion, CBLL1 is a promising drug target and biomarker for prostate and lung cancer. Its involvement in the ubiquitin signaling pathway and its role in the regulation of protein stability and localization make it an attractive target for new treatments. The inhibition of CBLL1 activity may be an effective way to treat these cancers, and CBLL1 may be a useful biomarker for their diagnosis and prognosis. Further studies are needed to

Protein Name: Cbl Proto-oncogene Like 1

Functions: E3 ubiquitin-protein ligase that mediates ubiquitination of several tyrosine-phosphorylated Src substrates, including CDH1, CTTN and DOK1 (By similarity). Targets CDH1 for endocytosis and degradation (By similarity). Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (PubMed:29507755). Its function in the WMM complex is unknown (PubMed:29507755)

The "CBLL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBLL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets